Novo Nordisk reported first-quarter 2026 results this morning and the print resets several assumptions about the oral GLP-1 race. Revenue came in at DKK 96.8 billion ($15.17 billion), a 32% increase at constant exchange rates and well above the $11.13 billion analyst consensus. The single most consequential data point: Wegovy pill (oral semaglutide 25 mg) generated approximately 1.3 million prescriptions in Q1 — what Novo characterized as the strongest-ever GLP-1 volume launch in the United States. Stock jumped 7% premarket to $48.06.

The Wegovy pill number isn’t just impressive in isolation. It reframes the competitive landscape for every oral GLP-1 in development.

The Wegovy Pill Performance Detail

The 1.3 million-prescription figure spans the January-through-March launch window. Wegovy pill revenue in Q1 came in at DKK 2,256 million ($353.6 million) — roughly twice the analyst consensus of DKK 1.16 billion. Cumulative prescriptions since launch now exceed 2 million.

Beyond the launch curve, the broader semaglutide franchise — Wegovy (injectable + pill), Ozempic, Rybelsus, and the newly launched oral Ozempic for T2D — now captures 65% of all new GLP-1 prescriptions in the United States. That’s a dominant new-patient share by any measure of the obesity drug market.

Novo’s guidance was tightened upward as a direct result: full-year 2026 adjusted sales and operating profit are now expected to decline 4–12% at constant exchange rates, versus the prior 5–13% range. The narrower guidance reflects Wegovy pill outperformance against earlier internal projections.

What 1.3 Million Means in Context

The Wegovy pill number puts the oral GLP-1 launch curve at a benchmark roughly five times higher than what competitors are running.

Eli Lilly’s Foundayo (orforglipron) — the first small-molecule oral GLP-1, approved April 1 — has accumulated roughly 7,000 weekly prescriptions through its Week 4 IQVIA reporting. The Foundayo launch trajectory is slower than the comparable Wegovy pill window in part because oral semaglutide is a higher-dose formulation of an already-established injectable molecule (subscribers and prescribers familiar with the brand), while Foundayo is a structurally distinct small molecule entering a category Novo already dominates.

The strategic implication: if Wegovy pill captures the first-line oral GLP-1 market while injectable Wegovy and Zepbound continue to capture first-line injectable, the addressable market for entrants like Foundayo and Viking’s VK2735 oral (Phase 3 starting Q4 2026) compresses. Lilly’s strategic response to this — which became visible at the European Congress on Obesity a week after Novo’s earnings — is to position Foundayo as a maintenance bridge after injectables rather than a first-line oral competitor.

The Pipeline Updates

The Q1 call surfaced three pipeline items relevant to the next 12–24 months of obesity drug development.

CagriSema Phase 3-B high-dose trial starting Q2 2026. Novo’s response to the REDEFINE 4 head-to-head failure against tirzepatide (February 2026) is to test a higher cagrilintide dose rather than abandon the program. The Phase 3-B trial aims to determine whether higher cagrilintide exposure can close the efficacy gap with tirzepatide. The CagriSema NDA review remains on track for the estimated October PDUFA.

Amycretin Phase 3 obesity program advancing. Both subcutaneous and oral amycretin formulations are advancing into Phase 3. Phase 2 data showed 24.3–24.4% weight loss at 36 weeks with the 60 mg subcutaneous dose — a profile that, if replicated in Phase 3, would be competitive with retatrutide’s 28.7% at 68 weeks on a per-week basis. Amycretin is increasingly visible as Novo’s true next-generation obesity asset.

Oral zenagamtide AMAZE 9 trial initiation targeted Q3 2026. A new program name to track. The trial will investigate oral zenagamtide in adults with obesity, joining a crowded oral GLP-1 development pipeline.

What This Means

For patients on injectable Wegovy or Zepbound considering an oral switch, the Wegovy pill commercial validation matters: there’s a working oral GLP-1 with broad prescriber familiarity, established insurance pathways (where coverage exists), and substantial real-world data accumulating from the 2-million-plus prescriptions to date. That’s a different commercial environment than what Foundayo entered into in April.

For the competitive landscape: the GLP-1 oral category is bifurcating. Wegovy pill is positioned as first-line oral. Foundayo’s competitive case, as it emerged at ECO 2026 a week after Novo’s earnings, is now built around the maintenance-after-injectables segment rather than first-line obesity prescribing. Viking’s oral VK2735 won’t reach market until 2028 at the earliest, by which point the segmentation will be more entrenched.

For the broader obesity drug picture: Novo’s 65% new-patient share — combined with the price cuts effective January 2027 and the just-announced Medicare GLP-1 Bridge program (covering Wegovy and Foundayo at $50/month copay starting July 1) — signals the GLP-1 market is moving past the early-adoption phase into mass deployment.

References

1. Novo Nordisk Q1 2026 Results: Adjusted Operating Profit Reached DKK 32,858 Million. Novo Nordisk Investor Release. May 6, 2026. Novo Nordisk
2. Novo Nordisk Q1 2026: Wegovy Sales Jump as the Pill Hits 1.3M Prescriptions. CNBC. May 6, 2026. CNBC
3. Novo Nordisk Q1 2026: Earnings Beat on Wegovy Pill Demand. Yahoo Finance. May 6, 2026.
4. Wegovy Pill Debut Fattens Novo Nordisk’s Profit Outlook. Benzinga. May 6, 2026. Benzinga
5. Novo Nordisk Ramps Up Obesity Fight, Advances Amycretin to Phase III. Clinical Trials Arena. May 2026. Clinical Trials Arena